Tag: Sanofi

Rare Disease Drug Approved, Receiving ODD

The U.S. Food and Drug Administration today approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy,...

Drug Giants Should Explain High Prices on Insulin

Sanofi, Eli Lilly and Novo Nordisk have been sent letters by US lawmakers requesting information on the increased costs of insulin in recent years and the companies’ profit from sales of these product...

GSK and Sanofi Take Part in FinnGen

GlaxoSmithKline and Sanofi have joined academic groups and other pharma companies to take part in Finland’s large scale genomics project, based on data from 500,000 biobank volunteers. FinnGen aims...

FDA Votes Divided on Sanofi’s Diabetes Drug

The future of Sanofi and Lexicon’s oral diabetes drug Zynquista hangs in the balance after an FDA advisory committee was split on whether the drug would benefit patients. The Endocrinologic and Met...

Sanofi to Develop Antibodies with BiXAb Platform

Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics. As part of the deal, Sanofi will use the BiXAb pla...

BioNTech and Sanofi to Co-develop Cancer Immunotherapy

French multinational pharmaceutical company Sanofi investing €80m in equity in BioNTech, which is claimed to be the Europe’s largest privately-held biopharmaceutical firm focused on the development of...

Sanofi Gives Back Rights for Drugs to MyoKardia

Sanofi has walked away from a four-year-old alliance with US biotech MyoKardia, handing back rights to three drugs for heart disease. The decision comes ahead of data readouts for two of the clinic...

Sanofi’s Pediatric Vaccine Approved by FDA

The US Food and Drug Administration (FDA) has approved Sanofi’s pediatric hexavalent combination vaccine for use in children between six weeks and five years of age. The vaccine, called Vaxelis, is...

Opiant and Sanofi to Develop Drinabant for ACO

Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO). AC...

Hong Kong stops vaccination service because of Sanofi-Aventis’ vaccines

malaria vaccine
Hong Kong's Department of Health as informed by Sanofi-Aventis, that it has decided to take a precautionary measure to suspend the supply of a batch of quadrivalent seasonal influenza vaccines.

Sanofi to establish a research institute in China

French pharmaceutical company Sanofi is planning to set up its first research institute in the eastern city of Suzhou (China) to further expand its presence in the world's most populous country.

Sanofi conducted the China Health Road Symposium in Shanghai

Sanofi held the China Health Road Symposium in Shanghai (China) during the first edition of China International Import Expo (CIIE) exhibition that was conducted for five days

Sanofi and Denali Therapeutics join forces to develop new drugs

Sanofi plans to collaborate with Denali Therapeutics on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.

EMA reviewed the tetravalent vaccine for prevention of dengue

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Dengvaxia (dengue tetravalent vaccine).

Evotec launches a new drug discovery initiative with Sanofi

drug discovery
Evotec AG announced that it has established an initiative with Sanofi through the launch of a BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.

Sanofi is running the pilot of AI solution with Researchably

Researchably (USA) announces the only AI solution which uses natural language processing (NLP) to read and review these scientific articles.